BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, Salgia R, Seetharam A, Sharma P, Sherman C, Tsoulfas G, Yao FY. Liver transplantation for hepatocellular carcinoma: Management after the transplant. Am J Transplant 2020;20:333-47. [PMID: 31710773 DOI: 10.1111/ajt.15697] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
Number Citing Articles
1 Kelava T, Turcic P, Markotic A, Ostojic A, Sisl D, Mrzljak A. Importance of genetic polymorphisms in liver transplantation outcomes. World J Gastroenterol 2020; 26(12): 1273-1285 [PMID: 32256016 DOI: 10.3748/wjg.v26.i12.1273] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Özdemir F, Baskiran A. The Importance of AFP in Liver Transplantation for HCC. J Gastrointest Canc 2020;51:1127-32. [DOI: 10.1007/s12029-020-00486-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Rios RS, Zheng KI, Zheng MH. Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma. Chin Med J (Engl) 2021;134:2911-21. [PMID: 34855640 DOI: 10.1097/CM9.0000000000001888] [Reference Citation Analysis]
4 Cullaro G, Rubin J, Mehta N, Yao F, Verna EC, Lai JC. Sex-Based Disparities in Hepatocellular Carcinoma Recurrence After Liver Transplantation. Transplantation 2020. [PMID: 33323764 DOI: 10.1097/TP.0000000000003575] [Reference Citation Analysis]
5 Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms. Z Gastroenterol 2022;60:e56-e130. [PMID: 35042248 DOI: 10.1055/a-1589-7568] [Reference Citation Analysis]
6 Lee SK, Lee SW, Jang JW, Bae SH, Choi JY, Yoon SK. Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma. Int J Mol Sci 2021;22:10271. [PMID: 34638613 DOI: 10.3390/ijms221910271] [Reference Citation Analysis]
7 Magro B, Pinelli D, De Giorgio M, Lucà MG, Ghirardi A, Carrobio A, Baronio G, Del Prete L, Nounamo F, Gianatti A, Colledan M, Fagiuoli S. Pre-Transplant Alpha-Fetoprotein > 25.5 and Its Dynamic on Waitlist Are Predictors of HCC Recurrence after Liver Transplantation for Patients Meeting Milan Criteria. Cancers (Basel) 2021;13:5976. [PMID: 34885087 DOI: 10.3390/cancers13235976] [Reference Citation Analysis]
8 Gong J, Li Y, Yu J, Wang T, Duan J, Hu A, He X, Zhu X. The predictive role of preoperative serum glutamate dehydrogenase levels in microvascular invasion and hepatocellular carcinoma prognosis following liver transplantation-a single center retrospective study. PeerJ 2021;9:e12420. [PMID: 34760395 DOI: 10.7717/peerj.12420] [Reference Citation Analysis]
9 Kwong AJ, Ghaziani TT, Yao F, Sze D, Mannalithara A, Mehta N. National Trends and Waitlist Outcomes of Locoregional Therapy Among Liver Transplant Candidates With Hepatocellular Carcinoma in the United States. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00830-2. [PMID: 34358718 DOI: 10.1016/j.cgh.2021.07.048] [Reference Citation Analysis]
10 Bhangui P. Reply. Liver Transpl 2021;27:932-3. [PMID: 33567154 DOI: 10.1002/lt.26008] [Reference Citation Analysis]
11 Miao W, Nie P, Yang G, Wang Y, Yan L, Zhao Y, Yu T, Yu M, Wu F, Rao W, Wang Z. An FDG PET/CT metabolic parameter-based nomogram for predicting the early recurrence of hepatocellular carcinoma after liver transplantation. Eur J Nucl Med Mol Imaging 2021. [PMID: 33813592 DOI: 10.1007/s00259-021-05328-w] [Reference Citation Analysis]
12 Ho CM, Hu RH, Wu YM, Ho MC, Lee PH. Cross-Match as an Immuno-Oncological Risk Factor for Hepatocellular Carcinoma Recurrence and Inferior Survival After Living Donor Liver Transplantation: A Call for Further Investigation. Clin Med Insights Oncol 2020;14:1179554920968774. [PMID: 33343205 DOI: 10.1177/1179554920968774] [Reference Citation Analysis]
13 Hessheimer AJ, Fondevila C. Posttransplantation HCC Surveillance: Impact on Outcome or Byproduct of Biology? Transplantation 2020;104:1997-8. [PMID: 31996664 DOI: 10.1097/TP.0000000000003140] [Reference Citation Analysis]
14 Chen H. Nutrient mTORC1 signaling contributes to hepatic lipid metabolism in the pathogenesis of non-alcoholic fatty liver disease. Liver Research 2020;4:15-22. [DOI: 10.1016/j.livres.2020.02.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
15 Brandi G, Ricci AD, Rizzo A, Zanfi C, Tavolari S, Palloni A, De Lorenzo S, Ravaioli M, Cescon M. Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases? Cancer Commun (Lond) 2020;40:461-4. [PMID: 32762027 DOI: 10.1002/cac2.12072] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Ho CM, Lee CH, Lee MC, Zhang JF, Chen CH, Wang JY, Hu RH, Lee PH. Survival After Treatable Hepatocellular Carcinoma Recurrence in Liver Recipients: A Nationwide Cohort Analysis. Front Oncol 2020;10:616094. [PMID: 33598433 DOI: 10.3389/fonc.2020.616094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Koch C, Bette T, Waidmann O, Filmann N, Schrecker C, Trojan J, Weiler N, Vermehren J, Schnitzbauer AA, Bechstein WO, Zeuzem S, Herrmann E, Welker MW. AFP ratio predicts HCC recurrence after liver transplantation. PLoS One. 2020;15:e0235576. [PMID: 32614912 DOI: 10.1371/journal.pone.0235576] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Ding J, Li HY, Zhang L, Zhou Y, Wu J. Hedgehog Signaling, a Critical Pathway Governing the Development and Progression of Hepatocellular Carcinoma. Cells 2021;10:123. [PMID: 33440657 DOI: 10.3390/cells10010123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Sha M, Tong Y, Xia Q. Living Donor Liver Transplantation for Patients With Hepatocellular Carcinoma: What Are the Optimal Criteria? Liver Transpl 2021;27:930-1. [PMID: 33539659 DOI: 10.1002/lt.26003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Zen Y, Srinivasan P, Kitagawa M, Suzuki K, Heneghan M, Prachalias A. De novo perihilar cholangiocarcinoma arising in the allograft liver 15 years post-transplantation for biliary atresia. Pathol Int 2020;70:563-7. [PMID: 32350971 DOI: 10.1111/pin.12944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Zhan J, Wu Y, Wang H, Liu J, Ma Q, Xiao K, Li Z, Li J, Luo F, Tan H. An injectable hydrogel with pH-sensitive and self-healing properties based on 4armPEGDA and N-carboxyethyl chitosan for local treatment of hepatocellular carcinoma. Int J Biol Macromol 2020;163:1208-22. [PMID: 32645496 DOI: 10.1016/j.ijbiomac.2020.07.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
22 Aggarwal A, Te HS, Verna EC, Desai AP. A National Survey of Hepatocellular Carcinoma Surveillance Practices Following Liver Transplantation. Transplant Direct 2021;7:e638. [PMID: 33324743 DOI: 10.1097/TXD.0000000000001086] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Lin B, He H, Zhang Q, Zhang J, Xu L, Zhou L, Zheng S, Wu L. Long non-coding RNA00844 inhibits MAPK signaling to suppress the progression of hepatocellular carcinoma by targeting AZGP1. Ann Transl Med 2020;8:1365. [PMID: 33313110 DOI: 10.21037/atm-20-3848] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Yao FY, Fidelman N, Mehta N. The Key Role of Staging Definitions for Assessment of Downstaging for Hepatocellular Carcinoma. Semin Liver Dis 2021;41:117-27. [PMID: 33788207 DOI: 10.1055/s-0040-1716565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Ma Z, Li S, Wang Y, Zhang J, Zeng X. Upregulation of a novel LncRNA AC104958.2 stabilized by PCBP2 promotes proliferation and microvascular invasion in hepatocellular carcinoma. Exp Cell Res 2021;407:112791. [PMID: 34418457 DOI: 10.1016/j.yexcr.2021.112791] [Reference Citation Analysis]
26 Pelizzaro F, Gambato M, Gringeri E, Vitale A, Cillo U, Farinati F, Burra P, Russo FP. Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Cancers (Basel) 2021;13:4882. [PMID: 34638365 DOI: 10.3390/cancers13194882] [Reference Citation Analysis]
27 Mehta N, Frenette C, Tabrizian P, Hoteit M, Guy J, Parikh N, Ghaziani TT, Dhanasekaran R, Dodge JL, Natarajan B, Holzner ML, Frankul L, Chan W, Fobar A, Florman S, Yao FY. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium. Gastroenterology 2021:S0016-5085(21)03284-4. [PMID: 34331914 DOI: 10.1053/j.gastro.2021.07.033] [Reference Citation Analysis]
28 Zhang L, Yang Z, Zhang S, Zhou K, Zhang W, Ling S, Sun R, Tang H, Wen X, Feng X, Song P, Xu X, Xie H, Zheng S. Polyploidy Spectrum Correlates with Immunophenotype and Shapes Hepatocellular Carcinoma Recurrence Following Liver Transplantation. JIR 2022;Volume 15:217-33. [DOI: 10.2147/jir.s345681] [Reference Citation Analysis]
29 Hussaarts KGAM, van Doorn L, Bins S, Sprengers D, de Bruijn P, van Leeuwen RWF, Koolen SLW, van Gelder T, Mathijssen RHJ. Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma. Pharmaceuticals (Basel). 2021;14:46. [PMID: 33435321 DOI: 10.3390/ph14010046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
30 Ossami Saidy RR, Postel MP, Pflüger MJ, Schoening W, Öllinger R, Gül-Klein S, Schmelzle M, Tacke F, Pratschke J, Eurich D. Minimization of Immunosuppressive Therapy Is Associated with Improved Survival of Liver Transplant Patients with Recurrent Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1617. [PMID: 33807392 DOI: 10.3390/cancers13071617] [Reference Citation Analysis]
31 Abrahamsson J, Sternby Eilard M, Rizell M, Bennett W, Åberg F. Reduced calcineurin inhibitor exposure with antibody induction and recurrent hepatocellular carcinoma after liver transplantation. Scand J Gastroenterol 2021;:1-8. [PMID: 34871120 DOI: 10.1080/00365521.2021.2010799] [Reference Citation Analysis]
32 Tejedor-Tejada J, Alonso-Martín C, Almohalla-Álvarez C, Valenzuela EF, Muñoz RN, Delgado LS, Martín CM, Sánchez-Martín F, García-Pajares F, Sánchez-Antolín G. Immunosuppressive Treatment With mTOR Inhibitors for Malignancies After Liver Transplantation: Long-Term Survival Retrospective Analysis. Transplant Proc 2020;52:1507-10. [PMID: 32213292 DOI: 10.1016/j.transproceed.2020.02.058] [Reference Citation Analysis]
33 Yang Z, Chen W, Zhu H, Zhang L, Zhou K, Tang H, Sun R, Huang Y, Xie H, Zheng S, Jia C. Methylation site APC112043544 as a potential biomarker for post-transplant hepatocellular carcinoma recurrence. Future Oncol 2022. [PMID: 35502765 DOI: 10.2217/fon-2021-1608] [Reference Citation Analysis]
34 Yang Z, Wang S, Tian XY, Xie QF, Zhuang L, Li QY, Chen CZ, Zheng SS. Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: Preliminary experience. Hepatobiliary Pancreat Dis Int 2020;19:365-70. [PMID: 32553774 DOI: 10.1016/j.hbpd.2020.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
35 Ma E, Li J, Xing H, Li R, Shen C, Zhang Q, Ma Z, Tao Y, Qin L, Zhao J, Wang Z. Development of a predictive nomogram for early recurrence of hepatocellular carcinoma in patients undergoing liver transplantation. Ann Transl Med 2021;9:468. [PMID: 33850865 DOI: 10.21037/atm-21-334] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Costentin C, Piñero F, Degroote H, Notarpaolo A, Boin IF, Boudjema K, Baccaro C, Podestá LG, Bachellier P, Ettorre GM, Poniachik J, Muscari F, Dibenedetto F, Hoyos Duque S, Salame E, Cillo U, Marciano S, Vanlemmens C, Fagiuoli S, Burra P, Van Vlierberghe H, Cherqui D, Lai Q, Silva M, Rubinstein F, Duvoux C, Boudjema K, Bachellier P, Conti F, Scatton O, Muscari F, Salame E, Bernard PH, Francoz C, Durand F, Dharancy S, Woehl M, Vanlemmens C, Laurent A, Radenne S, Dumortier J, Abergel A, Cherqui D, Barbier L, Houssel-debry P, Pageaux GP, Chiche L, Deledinghen V, Hardwigsen J, Gugenheim J, altieri M, Hilleret MN, Decaens T, Duvoux C, Piñero F, Chagas A, Costa P, Cristina de Ataide E, Quiñones E, Duque SH, Marciano S, Anders M, Varón A, Zerega A, Poniachik J, Soza A, Machaca MP, Arufe D, Menéndez J, Zapata R, Vilatoba M, Muñoz L, Menéndez RC, Maraschio M, Podestá LG, Mccormack L, Mattera J, Gadano A, Fatima Boin IS, Parente García JH, Carrilho F, Silva M, Notarpaolo A, Magini G, Miglioresi L, Gambato M, Benedetto FD, D’ambrosio C, Ettorre GM, Vitale A, Burra P, Fagiuoli S, Cillo U, Colledan M, Pinelli D, Magistri P, Vennarecci G, Colasanti M, Giannelli V, Pellicelli A, Baccaro C, Lai Q, Degroote H, Vlierberghe HV, Eduard C, Samuele I, Jeroen D, Jonas S, Jacques P, Chris V, Dirk Y, Peter M, Valerio L, Christophe M, Olivier D, Jean D, Roberto T, Paul LJ. R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100445] [Reference Citation Analysis]
37 Chen Z, Wang T, Chen C, Hong X, Yu J, Ma Y, Guo Y, Huang C, He X, Ju W, Chen M. Circulating Tumor Cell Is a Clinical Indicator of Pretransplant Radiofrequency Ablation for Patients with Hepatocellular Carcinoma. J Oncol 2021;2021:7776389. [PMID: 34712326 DOI: 10.1155/2021/7776389] [Reference Citation Analysis]
38 Wang P, Xu Y, Sun Y, Cheng J, Zhou K, Wu S, Hu B, Zhang Z, Guo W, Cao Y, Huang X, Zhou J, Fan J, Yang X. Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation. Liver Int 2021;41:562-73. [DOI: 10.1111/liv.14734] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]